What is King Pharmaceuticals's equity securities?

King Pharmaceuticals (KG) reported equity securities of $11.75M in Q1 2026.

What does equity securities mean?

Insurance company investments in equity securities (stocks, equity funds) measured at fair value.

King Pharmaceuticals KG Equity securities

Equity securities at other companies

Arch Capital GroupACGL

$1.77B+9.1%

Everest GroupEG

$177M+5.4%

Skyward Specialty Insurance Group, Inc.SKWD

$1.14M-98.9%

Selective Insurance GroupSIGI

$388.28M+45.7%

Reinsurance Group of AmericaRGA

$300M+96.1%

W.R. BerkleyWRB

$1.47B+28.3%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's equity securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's equity securities?: King Pharmaceuticals (KG) reported equity securities of $11.75M in Q1 2026.
What does equity securities mean?: Insurance company investments in equity securities (stocks, equity funds) measured at fair value.